

PTO/SB/97 (09-08)

Approved for use through 3/31/2007. OMB 0861-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


RECEIVED
CENTRAL FAX CENTER

DEC 04 2006

CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

On December 4, 2006
Date


Jacqueline M. Cohen
Attorney for Applicants
Reg. No.: 51,574
Telephone No: 302-885-4269

Items being Transmitted herewith regarding Attorney Docket No.100884-1 US include:

Response to Non-final Office Action mailed October 2, 2006 (pages 1-21); and
Appendices A to I (pages 1-57).

**RECEIVED
CENTRAL FAX CENTER****DEC 04 2006****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/533,764	First Named Inventor: Brown
371 Filing Date: May 4, 2005	Attorney Docket No.: 100884-1 US
Examiner: S. Moore	Group Art Unit: 1624
Customer No.: 22466	Confirmation No.: 2289
Title: 4-(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT

Sir:

In response to the Final Office Action dated October 2, 2006, please amend the above-identified application as follows and consider the following remarks.

Amendments to the Claims begin on page 2 of this paper.

Remarks/Arguments begin on page 13 of this paper.